This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
We thank Drs Tolosa and Sparber for their comments concerning our article "Bromocriptine in Huntington Chorea," which recently appeared in the Archives (33:517, 1976). In our study, doses greater than 40 mg of bromocriptine were not "toxic"; there was simply a conventional sigmoid dose-response relationship for the induction of chorea in both parkinsonian and huntingtonian patients. We could not find any evidence to support the view that the dopaminergic agonist that we were studying, bromocriptine, had any therapeutic action in Huntington disease. We do not take issue with Drs Tolosa's and Sparber's observations with apomorphine or to its possible mechanisms of action. We are confident that dopamine-receptor agonists like bromocriptine will lead to progress in the treatment of parkinsonism, but we are not as optimistic as Drs Tolosa and Sparber about their effectiveness in Huntington chorea.
Kartzinel R, Calne DB. Huntington Chorea-Reply. Arch Neurol. 1977;34(1):59. doi:10.1001/archneur.1977.00500130079021
Customize your JAMA Network experience by selecting one or more topics from the list below.